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SUMMARY
Aim: Insulin-like growth factor I (IGF-I) is a neuroprotective agent in animal models of
ischemic stroke. The purpose of this study was to determine whether systemically injected
IGF-I exerts its neuroprotective action by binding to IGF-I receptors in the brain after cross-
ing the blood–brain barrier, or via peripheral effects. Methods: To differentiate the central
effects of IGF-I from systemic effects, ischemic stroke was induced in conscious male Wistar
Kyoto rats by the injection of endothelin-1 adjacent to the middle cerebral artery in the
right hemisphere, while either the IGF-I receptor antagonist JB-1 or vehicle was introduced
into the right lateral ventricle. Results: Intravenous injection of recombinant human (rh)
IGF-I resulted in 50% reduction in infarct size, which was counteracted by the central
administration of JB-1. Furthermore, rhIGF-I was detected in both the ischemic and nonis-
chemic hemisphere. Conclusions: Systemically injected rhIGF-I passes the blood–brain
barrier and protects neurons via IGF-I receptors in the brain in rats with an ischemic stroke.
Introduction
Insulin-like growth factor I (IGF-I) exerts neuroprotective effects
in different experimental models of ischemic stroke [1]. In
humans, higher circulating levels of IGF-I measured early after
stroke onset have been associated with better outcome, sug-
gesting that systemic injection of IGF-I could be a treatment
option for stroke patients [2–5]. Several studies have suggested
that neuroprotection by IGF-I in preclinical stroke models may be
mediated by the modulation of several events of the ischemic cas-
cade including glial cell death, neuroinflammation, oxidative
stress, and inhibition of excitotoxicity [6]. Despite these data, it
remains uncertain whether systemically injected IGF-I exerts its
neuroprotective effects through binding to the receptors in the
brain, or through systemic effects. In the latter case, IGF-I-
mediated modulation of adhesion molecules on endothelial cells
or circulating leukocytes could affect the infiltration of leukocytes
(predominantly monocytes and neutrophils) in response to cere-
bral ischemia. Moreover, hyperglycemia exacerbates poor
outcome after stroke [7] and IGF-I exerts hypoglycemic effects
[8]. Therefore, it is possible that IGF-I positively influences the
outcome after ischemic stroke via the restoration of glucose levels.
In the current study, we assessed, for the first time, the trans-
port to the brain of systemically injected IGF-I and the putative
central effects of IGF-I on neuroprotection in a preclinical stroke
model. To dissect the central action component from the systemic
component, we combined systemic IGF-I administration with cen-
tral injection of the IGF-I receptor antagonist JB-1 [9]. We found
that systemically injected IGF-I reduced infarct size through cen-
tral actions via its receptor in the brain.
Materials and Methods
Surgery
Protocols for animal experiments were designed according to the
European Guidelines on Animal Experimentation and approved
by the Ethical Committee for Animal Experimentation of the Vrije
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Universiteit Brussel (VUB). Male albino Wistar Kyoto rats (WKYR:
Charles River Laboratories, L’Arbresle Cedex, France) were
housed in groups of four and allowed to recover from transport
and to habituate to their new environment in the animal house
for 1 week having free access to tap water and standard laboratory
chow.
Surgery for the induction of ischemic stroke was performed on
10- to 12-week-old male rats weighing 275–300 g as described
earlier [10]. The rats were anaesthetized by intraperitoneal injec-
tion of 75 mg/kg ketamine and 3.5 mg/kg diazepam. The stereo-
tactic coordinates for the injection of endothelin-1 (Et-1) close to
the middle cerebral artery (MCA) in the piriform cortex were
determined using the Paxinos and Watson rat brain atlas [11]
(coordinates relative to bregma: anterior/posterior +0.9 mm,
lateral +5.0 mm, and ventral +2.8 mm). A guide was implanted
using a stereotactic frame. In this model, the core of the infarct is
located in the striatum, whereas the penumbra is present in the
cortex and striatum. Postoperative pain treatment consisted of an
intraperitoneal injection of 5 mg/kg ketoprofen.
To address the role of central IGF-I receptors, a second guide
was implanted for the infusion of JB-1 into the right lateral ventri-
cle (coordinates relative to bregma; anterior/posterior 0.9, lateral
+1.4, and ventral +3.5) for intracerebroventricular administration
of JB-1. Furthermore, an indwelling catheter filled with 0.9%
NaCl was implanted in the left femoral vena and subcutaneously
tunneled to the back of the neck and exteriorized [12]. The cathe-
ter was made from 20-cm pyrogen-free polyethylene tubing
(internal diameter 0.58 mm; outer diameter 0.96 mm) (Portex
Limited, Hyte, Kent, UK).
Induction of Ischemic Stroke
Twenty-four hours after surgery, the guide positioned close to the
MCA in the piriform cortex was replaced by a cannula, and 6 lL
of 200 pmol Et-1 (Sigma, St Louis, MO, USA) in iso-osmotic Ring-
er’s solution was infused at a rate of 1 lL/min into freely moving
animals.
IGF-I Treatment and Administration of JB-1
The rats were randomly assigned to the treatment groups. IGF-I
was a gift from Ipsen NV (Merelbeke, Belgium). Doses of 300 lg
were prepared in 0.4 mL vehicle solution (0.9% NaCl) and
injected intravenously at 30 min after the insult via the catheter.
Placebo rats were injected with vehicle solution alone. The guide
in the right lateral ventricle was replaced by a cannula for two
injections of JB-1 at 30 min before and again at 15 min after Et-1
administration. For each injection, 10 lg JB-1 (Bachem, Buben-
dorf, Switzerland) in 3 lL 0.9% NaCl was infused at a rate of
1 lL/min.
Histology and Immunohistochemistry
Infarct sizes and the presence of neurons were determined at 24 h
after the insult. The rats received an intraperitoneal injection of
sodium pentobarbital and were subsequently transcardially per-
fused for 5 min with 0.9% NaCl followed by perfusion for 5 min
with a 4% phosphate-buffered paraformaldehyde solution (pH
7.42). Subsequently, the brains were postfixed in paraformalde-
hyde and the brain slices of 50 lm were made using a vibratome
(Leica VTS1000, Bensheim, Germany). The slices were kept at 4°C
in PBS containing 0.01% sodium azide.
Infarct size was assessed using a series of equidistant 50-lm sec-
tions, comprising every 4th section, from 4.70 to 1.80 mm from
bregma. The sections were mounted onto gelatin-coated micro-
scope slides and stained with cresyl violet. Infarct sizes were calcu-
lated using Image J software (NIH, version 1.43, http://www.ncbi.
nlm.nih.gov). The Cavalieri principle for the estimation of vol-
umes [13] was used to estimate the infarct size (v) using the fol-
lowing formula: v = d 9 Σa, where d is the distance between the
upper (rostral) surfaces of two consecutive analyzed sections and
a is the surface area of a section. Edema corrections were made
according to the following equation: infarct volume * (volume
contralateral side/volume ipsilateral side).
To detect the neurons, 50-lm coronal brain slices were
mounted on 3-aminopropyltriethoxylane (APES)-coated slides
and incubated with a mouse monoclonal anti-NeuN antibody
(1:1.000 in normal goat serum/PBS, Millipore, Temecula, CA,
USA, catalog number: MAB377) and a peroxidase-conjugated
sheep anti-mouse IgG as a second antibody (1:100 in normal goat
serum/PBS, GE Healthcare UK Limited, Little Chalfont, Bucking-
hamshire, UK, catalog number: NA931V) [14].
Micrographs were taken using a Canon Powershot G5 camera
(5.0-M pixel CCD) attached to a Zeiss Axioskop 40 microscope
(Oberkochen, Germany) with a plan-Neofluar lens (10 9 0.30).
Micrographs were processed using Adobe Photoshop CS3 for con-
version to black and white and to correct for vignetting and to
optimize contrast and image sharpening.
Assessment of IGF-I Transport to the Brain
Solutions containing 300 lg recombinant human rhIGF-I were
prepared as described above and injected subcutaneously at
30 min after the injection of Et-1 (stroke) or Ringer’s solution
(sham). The rats were sacrificed 90 min after the insult, perfused
with saline, followed by prelevation of the brain. Left and right
brain hemispheres were then snap-frozen and stored at 80°C.
Frozen hemispheres were homogenized in HEPES buffer (20 mM
HEPES pH 7.4 with phosphoric acid, NaOH, and 1.5 mM EDTA)
with protease inhibitor cocktail (Roche Diagnostics GmbH, Man-
nheim, Germany). Homogenates were then sonicated for 60 s at
high pulse rate and centrifuged at 12,000 9 g for 30 min at 4°C.
The supernatant was stored at 20°C. The concentration of
rhIGF-I in the supernatant was determined using a human IGF-I-
specific ELISA (ELISA Quantikine kit, R&D systems Bio-rad lab-
oratories, M€unchen, Germany). Total protein concentrations in
the homogenates were assessed using the Bradford method [15].
Determination of Blood rhIGF-I and Glucose
Levels
Blood samples were obtained by nicking the lateral tail vein with
a scalpel and the glucose levels were determined using the Accu
Chek (Aviva, Roche Diagnostics, Vilvoorde, Belgium) glucometer.
After the preparation of serum, the levels of rhIGF-I were mea-
sured as described above.
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Statistics
The mortality rate in the experiments with the JB-1 (Figure 1)
was 27.5%. For this study, 40 rats were used, five animals died
during surgery, and six rats died within one hour after the induc-
tion of stroke. In addition, one animal removed the guide, six ani-
mals were excluded after the histological assessment because of
an incorrect placement of one of the guides, and four rats were
excluded due to the damage of brain slices. In the study on IGF-I
transport (Figure 2B), 46 rats were used, two died during surgery,
and two died directly after the induction of stroke.
Statistical analysis was performed using GraphPad Prism (ver-
sion 4.03, GraphPad Software, San Diego, California, USA). Statis-
tical significance (P < 0.05) between two groups was assessed by
the paired or unpaired Student’s t-test. Statistical difference
between more than two groups was evaluated via the one-way
ANOVA followed by the Newman–Keuls multiple comparison test
or a two-way ANOVA followed by the Bonferroni posttest. All
data represent mean values SEM.
Results
Although IGF-I has been shown to pass the blood–brain barrier
(BBB) within 20 min after intravenous injection [16], it has never
been investigated whether the systemic administration of IGF-I
indeed leads to the interaction with its receptors in the brain or
whether the systemic effects are involved. To address the possible
direct effects of IGF-I on its receptors in the brain, we studied the
effects of the selective IGF-I receptor antagonist JB-1. This antago-
nist was injected into the right lateral ventricle at 60 and 15 min
before IGF-I injection. Figure 1 reveals that IGF-I effectively
reduced the infarct volumes and blocking the cerebral IGF-I recep-
tor by intraventricular administration of JB-1 significantly
(P < 0.05) reduced the neuroprotective effects of IGF-I. Represen-
tative micrographs of the infarcts are shown in Figure 1B–E. In
addition, immunohistochemical staining with NeuN, a marker for
neurons, shows that IGF-I partially reverses the reduction in
NeuN expression at the insult site and that this effect is also atten-
uated by JB-1 (micrographs in Figure 1F–I). According to the lit-
erature, the latter effect may reflect the stimulation of nuclear
factor kappa B (NFjB) by IGF-I, mostly acting as a survival factor
in neurons [17]. Figure 1A also shows that central injection of JB-
1 in the absence of IGF-I administration did not affect the infarct
volume, ruling out the possible effects of JB-1 through the inhibi-
tion of endogenous IGF-I. Taken together, these results suggest
that systemically administered IGF-I acts on the brain. Direct evi-
dence for IGF-I transport to the brain in a rat model for ischemic
stroke was obtained by measuring the amount of rhIGF-I in the
brain using a human IGF-I-specific ELISA after the systemic injec-
tion of rhIGF-I. We first measured rhIGF-I levels in the serum in
normal rats and found that rhIGF-I was detectable 5 min after
the injection and that peak levels of ca 700 ng/mL were obtained
20 min after injection (Figure 2A). One hour after rhIGF-I injec-
tion in stroke rats and sham-operated rats, we perfused the brain
with PBS and made tissue extracts of the ipsi- and contralateral
hemispheres. No IGF-I was detected after the injection of the vehi-
cle, confirming that the ELISA does not recognize rat IGF-I (data
not shown). Human IGF-I was detected in both hemispheres of
rhIGF-I-treated rats with ischemic stroke; however, the amount of
IGF-I in the ischemic hemisphere was significantly higher than in
the nonischemic hemisphere (Figure 2B). Remarkably, IGF-I was
also clearly detected in the ischemic hemisphere of sham-operated
rats. An explanation for this could be that part of the transport to
the brain is due to the disruption of the BBB by the placement of
the guide. It should be noted, however, that the induction of
stroke significantly increases the amount of IGF-I in the nonis-
chemic hemisphere, suggesting that ischemic stroke augments
IGF-I transport to the brain via a bona fide transport mechanism.
This idea is supported by the absence of BBB disruption in the
contralateral side as established by staining with Evan’s blue (data
not shown).
Both anesthesia by the injection of ketamine and the induction
of ischemic stroke may lead to acute hyperglycemia in rats
[18,19], which on its turn can trigger the disruption of the blood–
brain barrier [20,21]. Conversely, severe hypoglycemia may also
induce BBB damage [22]. Therefore, we assessed the blood glu-
cose levels in normal, stroke, and sham-operated rats that were
treated with rhIGF-I. It appeared that prestroke glucose levels
were normal and that rhIGF-I injection lowered glucose levels,
but did not induce severe hypoglycemia (Figure 2C). A reduction
in glucose levels by IGF-I administration has been shown before
in diabetic rats with ischemic stroke [23], and this could con-
tribute to neuroprotection in these animals.
Discussion
IGF-I has been tested as a treatment for focal cerebral ischemia in
animal models. It reduced infarct volumes and improved neuro-
logical outcome when administered topically on the cerebral cor-
tex or intracerebroventricularly [24]. The application of intranasal
IGF-I administration was effective, especially when administered
early after the insult [25]. Three studies revealed that systemic
injection of IGF-I also leads to neuroprotection [23,24,26]. The
current study proves for the first time that intravenously adminis-
tered IGF-I exerts neuroprotective actions via the direct interac-
tion with its receptors in the brain. Furthermore, systemically
administered IGF-I is indeed transported to the brain in our model
for ischemic stroke. These observations imply that therapeutic
interventions aiming to increase the transport of IGF-I to the brain
may enhance the efficacy of IGF-I treatment. The neuroprotective
effect of IGF-I is demonstrated by the finding that IGF-I attenuates
the loss of NeuN-positive cells. Because the implantation of the
catheter severely affected the neurological deficit score, the func-
tional outcome has not been assessed. However, it has been
demonstrated that even a smaller reduction in infarct size coin-
cides with an amelioration of the neurological deficit score [26].
It has been shown before that IGF-I can pass the BBB via a gen-
uine saturable transport system [27], probably involving IGF-I
receptors [28] and transcytosis across the capillary endothelium
[29]. It has also been suggested that IGF-I transport to the brain is
regulated by neuronal activity [30]. IGF-I can also enter the brain
through the transport across the choroid plexus, where IGF-I
binds to its membrane receptor, which interacts with the multi-
cargo membrane protein and transporter megaline/LRP2. The per-
imembrane domain of megaline is instrumental to the
internalization of IGF-I, and interestingly, the C-terminal region
ª 2016 John Wiley & Sons Ltd CNS Neuroscience & Therapeutics 22 (2016) 611–616 613







Figure 1 Central administration of JB-1 blocks
the neuroprotective effect of systemic IGF-I
injection. The effects of JB-1 on the infarct
volume are shown in Figure 1(A). Ischemic
stroke was induced in all groups by the
administration of endothelin-1 (Et-1). Control
experiments consisted of the administration of
vehicle solutions for JB-1 (saline) or IGF-I
(placebo). Representative micrographs of the
cresyl violet staining are shown in micrographs
1(B–E). Representative micrographs of NeuN
immunohistochemistry are demonstrated in
panels (F–I). (B+F): rats that received saline and
placebo (n = 4); (C+G): rats that received saline
and 300 lg IGF-I (n = 6); (D+I): rats that
received JB-1 and placebo (n = 3); (E+H): rats
that received JB-1 and IGF-I (n = 5). A statistical
significance was assessed by an one-way
ANOVA followed by the Newman–Keuls post
hoc tests. *Significant difference between the
groups (P < 0.05). **Significant difference
between the groups (P < 0.01).
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associates with a glycogen synthase kinase-3 (GSK-3), which acts
as a key regulator of IGF-I transport. Mutations of the regulatory
site of GSK-3 modulate IGF-I internalization, and pharmacological
inhibition of GSK-3 at the choroid plexus increases the internal-
ization of IGF-I [30–32]. It would be interesting to test whether
GSK-3 inhibitors can stimulate the transport of systemically
injected IGF-I across the BBB and increase the treatment efficacy
of IGF-I. The IGF-I receptor and LRP1, a variant of LRP2, are
expressed in brain microvessels [33,34] and could be involved in
this process. Indeed, LRP1 has already been associated with
endothelial transcytosis [35]. Upregulation of LRP1 expression in
endothelial cells in response to hypoxia [36] could play a role in
the augmentation of IGF-I transport into the ischemic hemi-
sphere. Alternatively, the release of proinflammatory mediators
triggered by ischemic stroke can also enhance the expression of
LRP1 [37]. Interestingly, insulin transport across the BBB also
involves a saturable mechanism, possibly via insulin receptors,
and this kind of transport can be modulated through proinflam-
matory mediators such as nitric oxide [38]. Production of these
factors in the ischemic hemisphere could explain the enhance-
ment of IGF-I transport in the nonischemic hemisphere. Alterna-
tively, the inhibition of GSK-3 or upregulation of IGF-I receptor
levels may also lead to an enhancement of IGF-I transport. Upreg-
ulation of IGF-I receptor levels in the rat models of ischemic stroke
has been shown before [39], but an early assessment of modula-
tion of IGF-I receptor expression in the BBB has not been
performed yet.
In order to evaluate the clinical applicability of IGF-I treatment,
the outcome also has to be determined at later time points. It has
been shown in the literature that neuroprotection by IGF-I can
persist for at least a week. A daily subcutaneous injection of 200 ug
IGF-I resulted in a decrease in infarct size and an amelioration of
the functional outcome at 7 days after the insult [24]. The current
study focused on the basic mechanism of IGF-I on early events of
the ischemic cascade occurring within the first 24 h. This is rele-
vant for stroke studies, because neuronal death predominantly
occurs within 1 day. In addition, we demonstrated that the win-
dow for IGF-I treatment is not longer than 4 h [26]. Hence, the
stimulation of IGF-I transport shortly after the insult could be very
effective. It remains to be established, however, whether putative
effects of IGF-I at later time points, targeting later events of the
ischemic cascade, also depend on the transport across the BBB.
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